Alzheimer Drug Lecanemab Gains Traditional FDA Approval

• DOI: 10.1001/jama.2023.12548
• Publication Date: 2023-07-19T15:00:49Z
• Authors: Emily Harris
• Keywords: Alzheimer Disease; United States Food and Drug Administration; Humans; Antibodies, Monoclonal, Humanized; Drug Approval; United States

Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2024 American Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal